Lyka Labs promoters settle case with Sebi in Rs 3.07 lakh over alleged violation of disclosure lapses

The order came after the applicants filed settlement applications for proposing to settle by neither "admitting nor denying the findings of fact and conclusions of law".

Published On 2023-03-23 07:45 GMT   |   Update On 2023-03-23 07:46 GMT
Advertisement

New Delhi: Kunal N Gandhi and Nehal N Gandhi, promoters of Lyka Labs has settled with capital markets regulator Sebi a case regarding alleged violation of disclosure lapses.

Kunal N Gandhi and Nehal N Gandhi (applicants) paid Rs 3.07 lakh as settlement charges to the regulator.

The order came after the applicants filed settlement applications for proposing to settle by neither ''admitting nor denying the findings of fact and conclusions of law''.

Advertisement

''The proceedings that may be initiated against the applicants for the violations are settled qua the applicants,'' Sebi's Whole Time Members' Ashwani Bhatia and Ananth Narayan G said in the settlement order passed on Monday.

In November 2021, Ipca Laboratories Ltd made an open offer for the purchase of shares of Lyka under the SAST (Substantial Acquisition of Shares and Takeovers) norms.

During the course of open offer, it was observed that there were three instances of delayed disclosures by Kunal N Gandhi and Nehal N Gandhi under SAST rules which were intimated by the merchant banker to Sebi.

The settlement application was filed before Sebi on November 17, 2022 and the High Powered Advisory Committee of the regulator on December 14, 2022 recommended the case be settled upon payment of the settlement charges on the basis of joint and several liability. After Kunal N Gandhi and Nehal N Gandhi paid the respective amount of Rs 3.07 lakh, Sebi issued the settlement order.

Read also: SEBI bans Lyka Labs for 3 years for manipulating GDR to raise Rs 37 crore



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News